Internal Jugular Vein Respiratory Variability as a Marker of Disease Severity in Infant Bronchiolitis

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-23
SponsorEskisehir Osmangazi University

About this trial

This prospective observational cohort study evaluates whether respiratory-cycle variation in internal jugular vein (IJV) diameter, measured by point-of-care ultrasound, correlates with clinical disease severity in infants 1-23 months of age presenting with acute bronchiolitis. Using a standardized M-mode protocol, the IJV Variability Index (\[IJVmax-IJVmin\]/IJVmax x 100) will be calculated and compared with the Wang Bronchiolitis Severity Score, four additional validated clinical severity instruments (Modified Tal Score, Respiratory Distress Assessment Instrument, Kristjansson Respiratory Score, Respiratory Assessment Change Score), oxygen saturation, respiratory rate, need for high-flow nasal cannula or supplemental oxygen, pediatric intensive care unit admission, and length of hospital stay. Concurrent lung and diaphragm point-of-care ultrasound will be performed to build a multimodal ultrasound severity model. No intervention is assigned; all ultrasound assessments are performed in addition to standard clinical care and do not alter treatment decisions.

Eligibility criteria

Qualifiers

Infants aged 1-23 months

Clinical diagnosis of acute bronchiolitis per AAP (2014) criteria (first wheezing episode following an upper respiratory infection prodrome, with tachypnea, retractions, and/or crackles)

Written informed consent obtained from parent/legal guardian

Evaluable within the first 6 hours of emergency department presentation

Disqualifiers

Underlying congenital heart disease

Chronic lung disease (bronchopulmonary dysplasia, cystic fibrosis)

Prior history of recurrent wheezing/suspected asthma

Anatomical abnormality of the neck or prior history of central venous catheterization or jugular vein thrombosis

Trial design

Treatments tested in this trial

  • Point-of-Care Ultrasonography

Treatment groups

120 Participants
are divided into 1 treatment group

Sponsors and collaborators